Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 sub-study MK3475-01F in previously treated KRAS G12C-mutant nonsquamous NSCLC
MOH_2026-02-01_015631Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of calderasib, patritumab deruxtecan, sacituzumab tirumotecan and cetuximab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Primary endpoints: Safety, Tolerability and 1 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
calderasibpatritumab deruxtecansacituzumab tirumotecancetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2026-02-01_015631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-02-01_015631.